online ISSN 2415-3176
print ISSN 1609-6371
logoExperimental and Clinical Physiology and Biochemistry
  • 5 of 7
ECPB 2021, 93(3): 39–47
Research articles

Modeling of experimental acute bronchopneumonia with pulmonary fibrosis


There is currently an urgent need to create an available experimental model to reproduce the main pathogenetic mechanisms of COVID-associated lung injury. Aim – development of the acute bronchopneumonia experimental model with the pulmonary fibrosis. A group of laboratory Wistar rats (n=20) with full observance of bioethical norms under thiopental anesthesia underwent surgery with the introduction into the trachea of sterile nylon thread 2.5 cm long and 0.2 mm thick to a depth of 2.5 cm; in the control group included 5 animals. For 28 days, the animals were observed and performed pathomorphological, cytological, hematological and microscopic examinations. During the observation, the cyanosis increased, breathing became difficult with the active involvement of the respiratory muscles, severe rales and crepitation were heard. Rectal temperature increased by 1–1.5 o C. On sectional examination after 7 days, the lungs were swollen, pale pink in color, had layers of fibrin, severe cyanosis, intra-tissue hemorrhage. After 21 days, these changes were supplemented by the development of atelectasis and fibrosis. On the 21st day, the granulocyte-lymphocyte index increased (1.5 times; p=0.003). Microscopic examination showed the development in the first week of acute exudative bronchopulmonary inflammation, in the second – the formation of peribronchial and alveolar abscesses, with their organization in the third week, with the subsequent development of diffuse parenchymal fibrosis and vascular hyalinosis. The model of acute aspiration bronchopneumonia in rats with the introduction of nylon thread into the trachea allows to obtain the main clinical and morphological manifestations of acute exudative-proliferative damage to the lungs with the development of pulmonary fibrosis.

Keywords: acute bronchopneumonia, experiment, fibrosis

Full text: PDF (Ukr) 2.06M

  1. 1. World Health Organization. Coronavirus disease (COVID-19) outbreak.
  2. 2. Qu L, Li J, Ren H. COVID-19: the epidemiology and treatment. British journal of hospital medicine. 2020;81(10):1-9.
  3. 3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;15;395(10223):497-506.
  4. 4. Suster S, Moran AC. Biopsy interpretation of the lung. 1st ed. Lippincott Williams & Wilkins, Wolters Kluwer; 2013. 417 p.
  5. 5. Franks TJ, Chong PY, Chui P, Galvin JR, Lourens RM, Reid A et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Human pathology. 2003;34(8):743-8.
  6. 6. Cai A, McClafferty B, Benson J, Ramgobin D, Kalayanamitra R, Shahid Z et al. COVID-19: Catastrophic Cause of Acute Lung Injury. South Dakota medicine : the journal of the South Dakota State Medical Association. 2020;73(6):252-60
  7. 7. Pelaia C, Tinello C, Vatrella A, De Sarro G, Pelaia G. Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications. Therapeutic advances in respiratory disease. 2020;14, 1753466620933508.
  8. 8. Winkler MS, Skirecki T, Brunkhorst FM, Cajander S, Cavaillon JM, Ferrer R et al. Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge. EBioMedicine. 2021;66,103291.
  9. 9. National Center for Advancing Translational Sciences. OpenData Portal.
  10. 10. Gurumurthy CB, Quadros RM, Richardson GP, Poluektova LY, Mansour SL, Ohtsuka M. Genetically modified mouse models to help fight COVID-19. Nature protocols. 2020;15(12):3777-87.
  11. 11. Leist SR, Dinnon KH 3rd, Schäfer A, Tse LV, Okuda K, Hou Y et al. A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. Cell. 2020;183(4):1070-85.e12.
  12. 12. Ehaideb SN, Abdullah ML, Abuyassin B, Bouchama A. Evidence of a wide gap between COVID-19 in humans and animal models: a systematic review. Critical care (London, England). 2020;24(1):594.
  13. 13. Hau J. Animal Models for Human Diseases. In: Conn P.M. (eds) Sourcebook of Models for Biomedical Research. Humana Press. 2008.
  14. 14. Williams K, Roman J. Studying human respiratory disease in animals--role of induced and naturally occurring models. The Journal of pathology. 2016;238(2):220-32.
  15. 15. Dietert K, Gutbier B, Wienhold SM, Reppe K, Jiang X, Yao L et al. Spectrum of pathogen- and model-specific histopathologies in mouse models of acute pneumonia. PloS ONE. 2017;12(11):e0188251.
  16. 16. Khaibunasova LR, Borovkova KE, Salmova JV. Bacterialnie infekcii legkih. Modeli na jivotnih. [Lung bacterial infections. Animal models]. Laboratory animals for science. 2020;2:51-9.
  17. 17. Kubyshkin AV, Fomochkina II. Elastoliticheskaya aktivnost' bronchoalveolyarnogo lavaja pri modelirovanyy vospalitelnogo processa v legkih. [Elastolytic activity of bronchoalveolar lavage in modeling the inflammatory process in the lungs]. Ukr. Biohim. Zhurn. 2008;80(1):89-95. [in Russian]
  18. 18. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. The New England journal of medicine. 2020;383(2):120-8.
  19. 19. Polidoro RB, Hagan RS, de Santis Santiago R, Schmidt NW. Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19. Frontiers in immunology. 2020;11:1626.
  20. 20. Alharthy A, Faqihi F, Memish ZA, Karakitsos D. Lung Injury in COVID-19-An Emerging Hypothesis. ACS chemical neuroscience. 2020;11(15):2156-8.

Програмування -